INM-089 for Age-Related Macular Degeneration
INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration (AMD).
Study shows that INM-089 improved retinal function and thickness of the retina
InMed has selected INM-089, a cannabinol (CBN) analog, for further preclinical development following several in vitro and in vivo ocular disease studies. Results from an in vivo AMD disease study demonstrated that INM-089 preserved retinal function and improved the thickness of the outer nuclear layer of the retina where the photoreceptors are located. Based on widely accepted ocular research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity.
INM-089 shows promising neuroprotective effects for age-related macular degeneration
InMed studied and compared the effects of several rare cannabinoids and cannabinoid analogs on various eye disease models. One cannabinoid analog, now INM-089, demonstrated its ability to proactively protect the nerve cells in the back of the eye in the retinal area, exhibiting its therapeutic potential in age-related macular degeneration (AMD).
INM-089 shows promising neuroprotective effects in the back of the eye, which may lead to the preservation of the retinal function. Neuroprotection in AMD remains an unmet medical need and a new treatment option may help solve this multifactorial disease.
Pipeline expanded with two pharmaceutical programs in ocular disease
INM-089 in development for AMD is InMed’s second ocular disease program. InMed is also studying the therapeutic effects of INM-088 for the potential treatment of glaucoma.
It was during this preclinical glaucoma research of INM-088 when InMed discovered the ability of a cannabinol analog, now INM-089, to proactively protect the nerve cells in the back of the eye. As a result of this discovery, InMed has expanded its ocular program to explore the use of this proprietary CBN analog, INM-089, in the treatment of AMD.
Why cannabinoids for ocular disease?
Mounting scientific research is pointing to the neuroprotective effects of cannabinoids, supporting its therapeutic potential in ocular diseases such as AMD and glaucoma, in which neuroprotection is key to preserving the nerve cells in the eyes and potentially slowing or reversing eye damage. Several preclinical studies conducted by InMed in three of its programs have consistently shown the neuroprotective effects of cannabinoids in well-recognized study models.
What is AMD? Does AMD cause blindness?
Age-related macular degeneration (AMD) is an eye disease that causes damage to the macula which is part of the retina at the back of the eye. The macula controls the sharp vision straight ahead of you, and damage to the macular affects a person’s central vision.
AMD is common amongst the elderly and is a leading cause of vision loss. While it does not cause complete blindness, those with AMD will find it difficult to read, drive or do simple things around the home.
What are the types of AMD and how are they different?
There two primary types of AMD – dry AMD and wet AMD.
Dry AMD is the most common form of AMD, accounting for 80% of AMD cases. Dry AMD typically takes several years to progress and happens in three stages.
Wet AMD progresses quickly and occurs when abnormal blood vessels grow at the back of the eye causing macular damage.
What is the risk of AMD and how many people are affected?
It’s estimated that 11 million Americans have AMD. AMD is common among older adults. Those 50 or older, smoke, have a diet of high saturated fat, or have high blood pressure are at higher risk of AMD.
Early detection is key to slow down the progression of AMD. A sign of AMD is when straight lines look wavy.
What treatments are available for people with AMD?
Currently, there are no approved pharmaceutical treatments for people with dry age-related macular degeneration, which accounts for 80% of AMD cases. There are surgical implants and ongoing clinical drug trials. An ophthalmologist may recommend specific vitamins to slow the progression of AMD in its intermediate stage. There is a large unmet medical need for patients with dry AMD as there are no treatments for later-stage dry AMD in which the vision loss impedes one’s ability to do their everyday activities.
In the last decade, anti-VEGF injection treatment were introduced, offering hope to patients with wet AMD and in many cases this treatment stabilized and saved their vision.